Omega-3 2100 with CoQ10 Natural Orange Flavor
Goals
$42.49 $1.41 per serving
Product analysis
Omega-3 2100 with CoQ10 Natural Orange Flavor combines omega-3s for triglyceride metabolism with CoQ10 for normal cellular energy processes. The added CoQ10 offers weak value.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality30
The omega-3s use ethyl esters, which offer moderate absorption potential. The unspecified CoQ10 form leaves its absorption quality uncertain.
Ingredient Transparency69
Ingredient amounts are stated, but some forms are not identified. That limits a full comparison of ingredient quality.
Value For Money44
The omega-3 amount offers good value for its cost. The CoQ10 contribution is less economical, which weakens the combination’s price appeal.
Customer Satisfaction72
Customer feedback is very positive, though the number of ratings is relatively limited. Ratings reflect satisfaction and cannot establish effectiveness or safety.
Product Focus79
Omega-3s and CoQ10 connect most clearly to triglyceride metabolism and selected cardiovascular measures. Wider energy and skin benefits remain preparation-dependent and do not establish an added benefit from combining them.
- Format
Softgel - Container
- 90 Softgel(s)
- Per serving
- $1.41
- Customer rating
- 4.8 · 55 ratings
Goals
Impact
High effect
Coenzyme Q-10 · 150 mg
Impact
Highest effect
Coenzyme Q-10 · 150 mg
Impact
Highest effect
Coenzyme Q-10 · 150 mg
DHA (Docosahexaenoic Acid) Not classified
No linked studies yet.
Impact
Moderate effect
Coenzyme Q-10 · 150 mg
Impact
High effect
Omega-3 · 2100 mg
Impact
Highest effect
Coenzyme Q-10 · 150 mgOmega-3 · 2100 mg
Impact
Highest effect
Omega-3 · 2100 mgCoenzyme Q-10 · 150 mg
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Calories | 30 Calorie(s) | |
Total Fat | 2.5 Gram(s) | |
Cholesterol | 10 mg | |
Protein | 1 Gram(s) | |
Total Omega-3 Fatty Acids (Omega-3 Fatty Acids Ethyl Ester) | 2100 mg | |
Coenzyme Q10 | 150 mg |
Coenzyme Q-10 · 150 mg OverallScore38
Omega-3 (Omega-3 Fatty Acids Ethyl Ester) · 2100 mg OverallScore61
The serving lists 1350 mg EPA and 600 mg DHA. The cost per gram of combined EPA and DHA is moderate. The omega-3s are in ethyl esters form. The oil amount is unavailable, leaving concentration unclear.
How this ingredient is rated
Active Ingredient Quality & Bioavailability70
The omega-3s are in ethyl esters form. An antioxidant is included, though its identity is not specified here.
Molecular Form & Absorption Potential
The omega-3s are in ethyl esters form.
Source Purity & Oxidative Protection
A preferred oil source and antioxidant are noted, though their details are not specified here.
Dose, Safety & Label Transparency43
The serving lists 1350 mg EPA and 600 mg DHA. The oil amount is unavailable, so concentration is unknown.
EPA & DHA Label Specificity
The serving lists 1350 mg EPA and 600 mg DHA.
Active Ingredient Concentration
The oil amount is unavailable, so the EPA and DHA concentration is unknown.
Third-Party Purity Verification
A qualifying independent certification or purity standard is not noted.
Value80
The cost per gram of combined EPA and DHA is moderate.
Price per 1000mg of EPA+DHA
The cost per gram of combined EPA and DHA is moderate.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Effects of Coenzyme Q10 Supplementation on Lipid Profiles in Adults: A Meta-analysis of Randomized Controlled Trials.
- Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with metabolic-dysfunction associated steatotic liver disease: a randomized double-blind, placebo-controlled trial.
- The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial.
- [Coenzyme Q-10 in the treatment of patients with chronic heart failure and reduced left ventricular ejection fraction: systematic review and meta-analysis].
- Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial.
- Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials.
- Coenzyme Q10 Supplementation in Athletes: A Systematic Review.
- Effectiveness of Coenzyme Q10 Supplementation for Reducing Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Antifatigue effects of coenzyme Q10 during physical fatigue.
- Effect of coenzyme Q10 supplementation on fatigue: A systematic review of interventional studies.
- Ubiquinol Ameliorates Endothelial Dysfunction in Subjects with Mild-to-Moderate Dyslipidemia: A Randomized Clinical Trial.
- Dose-Response Effect of Coenzyme Q10 Supplementation on Blood Pressure among Patients with Cardiometabolic Disorders: A Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Effects of Coenzyme Q10 on Lipid, Glycemic, and Inflammatory Markers in Metabolic Disorders: A Systematic Review and Meta-Analysis.
- Treatment of coenzyme Q10 for 24 weeks improves lipid and glycemic profile in dyslipidemic individuals.
- Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
- Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).
- Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis.
- Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease.
- Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
- The effect of coenzyme Q10 supplementation on inflammatory and endothelial dysfunction markers in overweight/obese polycystic ovary syndrome patients.